Reduced Plasma MiR-146a Is a Predictor of Poor Coronary Collateral Circulation in Patients with Coronary Artery Disease

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2017 Jan 5

PMID 28050558

Citations 16

Authors

Junnan Wang

Youyou Yan

Dandan Song

Bin Liu

Affiliations

Soon will be listed here.

Abstract

Coronary collateral circulation (CCC), an alternative blood supply for ischemic myocardium, improves survival rates among patients with coronary artery disease (CAD). However, there remains a lack of biomarkers to discriminate between patients with poor or good CCC. In this study, we aimed to observe the relationship between plasma microRNA-146a (miR-146a) levels and the coronary collateral circulation (CCC). Additionally, we aimed to explore whether the plasma miR-146a level could serve as a blood-based biomarker for CCC in patients with CAD. We measured the plasma levels of vascular endothelial growth factor A (VEGF-A) and miR-146a in patients with CCC by ELISA and real-time PCR, respectively, according to the Rentrop grades. The results showed that the plasma miR-146a level is significantly increased in CAD patients with good CCC and significantly decreased in those with poor CCC. In contrast, although VEGFA expression in patients followed a similar trend as the CCC, the differences between the groups were not statistically significant. There was a positive correlation between plasma miR-146a levels and the Rentrop grading. In addition, receiver operator characteristic analysis showed that miR-146a could be a potent biomarker for identifying patients with poor CCC.

Citing Articles

Lack of association between the -2549 insertion/deletion variant of vascular endothelial growth factor and coronary artery disease in the Turkish population.

Yigit S, Nursal A, Celik A, Aci R, Askeroglu E Rev Assoc Med Bras (1992). 2024; 70(10):e20240333.

PMID: 39536247 PMC: 11554327. DOI: 10.1590/1806-9282.20240333.

Vascular Endothelial Growth Factor (VEGF) and Its Role in the Cardiovascular System.

Florek K, Mendyka D, Gomulka K Biomedicines. 2024; 12(5).

PMID: 38791016 PMC: 11117514. DOI: 10.3390/biomedicines12051055.

Combining inflammatory miRNA molecules as diagnostic biomarkers for depression: a clinical study.

Bras J, Pinto S, von Doellinger O, Prata J, Coelho R, Barbosa M Front Psychiatry. 2023; 14:1227618.

PMID: 37575572 PMC: 10413105. DOI: 10.3389/fpsyt.2023.1227618.

Bioinformatic Analyses of Peripheral Blood Transcriptome Identify Altered Neutrophil-Related Pathway and Different Transcriptomic Profiles for Acute Pancreatitis in Patients with and without Chylomicronemia Syndrome.

Liu C, Dai Y Biomolecules. 2023; 13(2).

PMID: 36830652 PMC: 9953624. DOI: 10.3390/biom13020284.

Integrative analyses of immune-related biomarkers and associated mechanisms in coronary heart disease.

Zhang L, Li G, Liang B, Su X, Xie H, Sun H BMC Med Genomics. 2022; 15(1):219.

PMID: 36266609 PMC: 9585797. DOI: 10.1186/s12920-022-01375-w.

References

Hoefer I, van Royen N, Rectenwald J, Deindl E, Hua J, Jost M . Arteriogenesis proceeds via ICAM-1/Mac-1- mediated mechanisms. Circ Res. 2004; 94(9):1179-85. DOI: 10.1161/01.RES.0000126922.18222.F0. View

Hakimzadeh N, Piek J . MicroRNAs to take the place of collateral flow index measurements and Rentrop scoring?-Reply to Papageorgiou et al. Ann Transl Med. 2016; 4(15):297. PMC: 4980374. DOI: 10.21037/atm.2016.07.26. View

Ajit S . Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors (Basel). 2012; 12(3):3359-69. PMC: 3376561. DOI: 10.3390/s120303359. View

Hakimzadeh N, Nossent A, van der Laan A, Schirmer S, de Ronde M, Pinto-Sietsma S . Circulating MicroRNAs Characterizing Patients with Insufficient Coronary Collateral Artery Function. PLoS One. 2015; 10(9):e0137035. PMC: 4558025. DOI: 10.1371/journal.pone.0137035. View

Grover T, Parker T, Zenge J, Markham N, Kinsella J, Abman S . Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol. 2003; 284(3):L508-17. DOI: 10.1152/ajplung.00135.2002. View

Kuehbacher A, Urbich C, Zeiher A, Dimmeler S . Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res. 2007; 101(1):59-68. DOI: 10.1161/CIRCRESAHA.107.153916. View

Lu Z, Li R, Zhou H, Huang J, Qi J, Su Z . Rescue of hypertension-related impairment of angiogenesis by therapeutic ultrasound. Am J Transl Res. 2016; 8(7):3087-96. PMC: 4969445. View

Yamasaki K, Nakasa T, Miyaki S, Ishikawa M, Deie M, Adachi N . Expression of MicroRNA-146a in osteoarthritis cartilage. Arthritis Rheum. 2009; 60(4):1035-41. PMC: 2670476. DOI: 10.1002/art.24404. View

Elsman P, van t Hof A, de Boer M, Hoorntje J, Suryapranata H, Dambrink J . Role of collateral circulation in the acute phase of ST-segment-elevation myocardial infarction treated with primary coronary intervention. Eur Heart J. 2004; 25(10):854-8. DOI: 10.1016/j.ehj.2004.03.005. View

10.

Khoo V, Shen L, Zhao L, Khoo V, Loo G, Richards A . Determination of the severity of underlying lesions in acute myocardial infarction on the basis of collateral vessel development. Coron Artery Dis. 2014; 25(6):493-7. DOI: 10.1097/MCA.0000000000000115. View

11.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K . Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10):997-1006. DOI: 10.1038/cr.2008.282. View

12.

Rubanyi G . Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors. Mol Ther. 2013; 21(4):725-38. PMC: 3616542. DOI: 10.1038/mt.2013.13. View

13.

Zhu K, Pan Q, Zhang X, Kong L, Fan J, Dai Z . MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. Carcinogenesis. 2013; 34(9):2071-9. DOI: 10.1093/carcin/bgt160. View

14.

Cheng H, Sivachandran N, Lau A, Boudreau E, Zhao J, Baltimore D . MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med. 2013; 5(7):1017-34. PMC: 3721471. DOI: 10.1002/emmm.201202318. View

15.

Karpanou E, Vyssoulis G, Skoumas J, Zervopoulos G, Moundaki V, Toutouzas P . Significance of arterial hypertension on coronary collateral circulation development and left ventricular function in coronary artery disease. J Hypertens Suppl. 1988; 6(4):S151-3. DOI: 10.1097/00004872-198812040-00044. View

16.

Tomasetti M, Staffolani S, Nocchi L, Neuzil J, Strafella E, Manzella N . Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem. 2012; 45(7-8):575-81. DOI: 10.1016/j.clinbiochem.2012.02.009. View

17.

Bhaumik D, Scott G, Schokrpur S, Patil C, Campisi J, Benz C . Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2008; 27(42):5643-7. PMC: 2811234. DOI: 10.1038/onc.2008.171. View

18.

Kim I, Moon S, Park S, Chae S, Koh G . Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res. 2001; 89(6):477-9. DOI: 10.1161/hh1801.097034. View

19.

Batkai S, Thum T . MicroRNAs in hypertension: mechanisms and therapeutic targets. Curr Hypertens Rep. 2011; 14(1):79-87. DOI: 10.1007/s11906-011-0235-6. View

20.

Huang Y, Liu Y, Li L, Su B, Yang L, Fan W . Involvement of inflammation-related miR-155 and miR-146a in diabetic nephropathy: implications for glomerular endothelial injury. BMC Nephrol. 2014; 15:142. PMC: 4236663. DOI: 10.1186/1471-2369-15-142. View